Solid Biosciences(SLDB)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SLDB Solid Biosciences

盘前交易 02-03 05:10:13 EST

6.43

-0.03

-0.46%

最高6.56	最低6.35	成交量103.32万
今开6.40	昨收6.46	日振幅3.25%
总市值5.01亿	流通市值2.42亿	总股本7,791万
成交额665.21万	换手率2.75%	流通股本3,761万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SLDB","market":"US","secType":"STK","nameCN":"Solid Biosciences","latestPrice":6.43,"timestamp":1770066000000,"preClose":6.46,"halted":0,"volume":1033234,"delay":0,"changeRate":-0.0046439628482972525,"floatShares":37613175,"shares":77910239,"eps":-2.48,"marketStatus":"盘前交易","change":-0.03,"latestTime":"02-03 05:10:13 EST","open":6.4,"high":6.56,"low":6.35,"amount":6652061.232314999,"amplitude":0.032508,"askPrice":7.38,"askSize":100,"bidPrice":5.89,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.48,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770129000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1516942800000,"exchange":"NASDAQ","adjPreClose":6.43,"postHourTrading":{"tag":"盘后","latestPrice":6.519,"preClose":6.43,"latestTime":"19:11 EST","volume":36193,"amount":232765.42,"timestamp":1770077507585,"change":0.089,"changeRate":0.013841,"amplitude":0.013841},"volumeRatio":1.6893403390262836,"impliedVol":1.3354,"impliedVolPercentile":0.54},"requestUrl":"/m/hq/s/SLDB","defaultTab":"news","newsList":[{"id":"2605477800","title":"Solid Biosciences Inc.盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605477800","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605477800?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:58","pubTimestamp":1769093900,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日22时58分，Solid Biosciences Inc.股票出现异动，股价急速拉升5.00%。截至发稿，该股报6.47美元/股，成交量10.966万股，换手率0.14%，振幅5.03%。Solid Biosciences Inc.股票所在的生物技术行业中，整体涨幅为0.74%。其相关个股中，60 Degrees Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Cabaletta Bio, Inc.涨幅较大，60 Degrees Pharmaceuticals, Inc.、Oragenics Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为10751.05%、357.62%、272.63%，振幅较大的相关个股有60 Degrees Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Greenwich Lifesciences, Inc.，振幅分别为131.00%、69.40%、21.53%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122225820953defd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122225820953defd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SLDB"],"gpt_icon":0},{"id":"2603985947","title":"Solid Biosciences Inc.盘中异动 大幅拉升5.04%报5.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603985947","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603985947?lang=zh_cn&edition=full","pubTime":"2026-01-14 23:16","pubTimestamp":1768403806,"startTime":"0","endTime":"0","summary":"北京时间2026年01月14日23时16分，Solid Biosciences Inc.股票出现波动，股价急速上涨5.04%。截至发稿，该股报5.42美元/股，成交量10.4137万股，换手率0.13%，振幅4.46%。Solid Biosciences Inc.股票所在的生物技术行业中，整体涨幅为0.01%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114231646a71ac900&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114231646a71ac900&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLDB","BK4139"],"gpt_icon":0},{"id":"1117152768","title":"Solid Biosciences公布2026年展望，强调神经肌肉与心脏管线进展及新一代衣壳AAV-SLB101的扩大可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1117152768","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117152768?lang=zh_cn&edition=full","pubTime":"2026-01-14 05:16","pubTimestamp":1768338994,"startTime":"0","endTime":"0","summary":"Solid Biosciences（纳斯达克代码：SLDB）近日发布了其2026年战略展望，重点突出了公司在神经肌肉疾病和心脏疾病治疗管线方面取得的显著进展。报告同时披露，公司下一代基因治疗衣壳AAV-SLB101的可及性将进一步扩大，为更多患者带来希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLDB"],"gpt_icon":0},{"id":"1129514473","title":"Solid Biosciences旗下SGT-212双路径基因疗法获FDA孤儿药认定 用于治疗弗里德赖希共济失调","url":"https://stock-news.laohu8.com/highlight/detail?id=1129514473","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129514473?lang=zh_cn&edition=full","pubTime":"2026-01-13 05:16","pubTimestamp":1768252619,"startTime":"0","endTime":"0","summary":"Solid Biosciences宣布，其研发的SGT-212双路径基因疗法已获得美国食品药品监督管理局授予的孤儿药认定，适应症为弗里德赖希共济失调。获得该认定后，Solid Biosciences将在药物开发和商业化过程中享受一系列政策支持，包括临床试验费用税收抵免、豁免部分申请费用以及上市后七年的市场独占权。弗里德赖希共济失调是一种遗传性神经系统疾病，目前尚无有效治疗方法。SGT-212通过双路径给药机制，有望为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLDB"],"gpt_icon":0},{"id":"1157703345","title":"Solid Biosciences：完成1B期Falcon试验首名受试者给药，初步数据预计2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1157703345","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157703345?lang=zh_cn&edition=full","pubTime":"2026-01-13 05:16","pubTimestamp":1768252580,"startTime":"0","endTime":"0","summary":"Solid Biosciences（SLDB）宣布，其1B期Falcon临床试验已完成对首位参与者的给药程序。该试验旨在评估其在研疗法的安全性与有效性。\n公司预计将于2026年下半年获得并公布这项研究的初步数据。此次进展标志着该药物临床开发计划中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLDB"],"gpt_icon":0},{"id":"1199313975","title":"Solid Biosciences首例受试者接受首创性1B期Falcon试验给药，评估SGT-212双通路基因疗法治疗弗里德赖希共济失调","url":"https://stock-news.laohu8.com/highlight/detail?id=1199313975","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199313975?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:08","pubTimestamp":1768223281,"startTime":"0","endTime":"0","summary":"生物技术公司Solid Biosciences宣布，其针对弗里德赖希共济失调研发的SGT-212双通路基因疗法，在首创性1B期Falcon临床试验中已完成对首例受试者的给药。该试验旨在评估这种创新疗法的安全性与初步疗效，标志着公司在该疾病领域的基因治疗探索迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLDB"],"gpt_icon":0},{"id":"2601857016","title":"Solid Biosciences Inc.盘中异动 早盘股价大跌5.23%报5.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601857016","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601857016?lang=zh_cn&edition=full","pubTime":"2026-01-06 00:20","pubTimestamp":1767630014,"startTime":"0","endTime":"0","summary":"北京时间2026年01月06日00时20分，Solid Biosciences Inc.股票出现异动，股价急速下挫5.23%。截至发稿，该股报5.17美元/股，成交量57.7645万股，换手率0.74%，振幅5.69%。Solid Biosciences Inc.股票所在的生物技术行业中，整体跌幅为1.95%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106002014a6f6ac9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106002014a6f6ac9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SLDB"],"gpt_icon":0},{"id":"2593734104","title":"2026美股生物科技板块怎么投资？杰富瑞：关注这6大首选股、7大潜力标的和5大并购目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2593734104","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593734104?lang=zh_cn&edition=full","pubTime":"2025-12-25 06:00","pubTimestamp":1766613621,"startTime":"0","endTime":"0","summary":"杰富瑞近日发布了关于2026年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。","market":"sg","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385521.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"2026美股生物科技板块怎么投资？杰富瑞：关注这6大首选股、7大潜力标的和5大并购目标","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["TNGX","ORIC","SLDB","TYRA","LENZ","TSHA"],"gpt_icon":1},{"id":"1150848586","title":"Solid Biosciences将在第22届全球心血管临床试验论坛上展示其专有的下一代Aav-Slb101载体和心脏基因疗法管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1150848586","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150848586?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:03","pubTimestamp":1765199021,"startTime":"0","endTime":"0","summary":"Solid Biosciences将在第22届全球心血管临床试验论坛上展示其专有的下一代Aav-Slb101载体和心脏基因疗法管线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","BK4139"],"gpt_icon":0},{"id":"1143964304","title":"Solid Biosciences 获得 FDA 对 Sgt-212 双途径给药基因疗法在弗里德里希共济失调症的罕见儿童疾病指定","url":"https://stock-news.laohu8.com/highlight/detail?id=1143964304","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143964304?lang=zh_cn&edition=full","pubTime":"2025-12-01 21:03","pubTimestamp":1764594221,"startTime":"0","endTime":"0","summary":"Solid Biosciences 获得 FDA 对 Sgt-212 双途径给药基因疗法在弗里德里希共济失调症的罕见儿童疾病指定","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLDB"],"gpt_icon":0},{"id":"2585517467","title":"Solid Biosciences Inc.盘中异动 临近午盘股价大涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585517467","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585517467?lang=zh_cn&edition=full","pubTime":"2025-11-22 00:51","pubTimestamp":1763743869,"startTime":"0","endTime":"0","summary":"北京时间2025年11月22日00时51分，Solid Biosciences Inc.股票出现异动，股价急速拉升5.16%。截至发稿，该股报4.69美元/股，成交量30.5265万股，换手率0.39%，振幅5.02%。Solid Biosciences Inc.股票所在的生物技术行业中，整体涨幅为0.91%。其相关个股中，Celularity Inc C/Wts 16/07/2026 、Osr Holdings, Inc.、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025涨幅较大，Osr Holdings, Inc.、Pasithea Therapeutics Corp.、Psyence Biomedical Ltd.较为活跃，换手率分别为439.03%、20.09%、19.67%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Osr Holdings, Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 ，振幅分别为63.22%、49.71%、47.00%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251122005109a709721d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251122005109a709721d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLDB","BK4139"],"gpt_icon":0},{"id":"2585815505","title":"Solid Biosciences Inc.盘中异动 早盘快速上涨5.58%报4.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585815505","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585815505?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:36","pubTimestamp":1763649401,"startTime":"0","endTime":"0","summary":"北京时间2025年11月20日22时36分，Solid Biosciences Inc.股票出现异动，股价快速拉升5.58%。截至发稿，该股报4.73美元/股，成交量2.9096万股，换手率0.04%，振幅3.56%。Solid Biosciences Inc.股票所在的生物技术行业中，整体涨幅为1.23%。其相关个股中，Abpro Holdings Inc C/Wts 12/11/2029 、Annexon, Inc.、Design Therapeutics, Inc.涨幅较大，Psyence Biomedical Ltd.、Clearmind Medicine Inc.、Plus Therapeutics, Inc.较为活跃，换手率分别为935.27%、26.40%、11.90%，振幅较大的相关个股有Seres Therapeutics, Inc.、Biorestorative Therapies, Inc.、康乃德生物，振幅分别为20.15%、16.78%、11.11%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120223642a706f838&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120223642a706f838&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLDB","BK4139"],"gpt_icon":0},{"id":"1181919598","title":"Solid Biosciences获得英国创新许可与接入途径下的创新护照资格，针对杜兴肌营养不良症的实验性基因疗法Sgt-003","url":"https://stock-news.laohu8.com/highlight/detail?id=1181919598","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181919598?lang=zh_cn&edition=full","pubTime":"2025-11-06 21:22","pubTimestamp":1762435335,"startTime":"0","endTime":"0","summary":"Solid Biosciences获得英国创新许可与接入途径下的创新护照资格，针对杜兴肌营养不良症的实验性基因疗法Sgt-003","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLDB"],"gpt_icon":0},{"id":"1110934243","title":"Solid Biosciences发布2025年第三季度财务业绩，并提供Inspire Duchenne临床试验进展及计划中的监管讨论更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1110934243","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110934243?lang=zh_cn&edition=full","pubTime":"2025-11-04 05:06","pubTimestamp":1762203995,"startTime":"0","endTime":"0","summary":"Solid Biosciences发布2025年第三季度财务业绩，并提供Inspire Duchenne临床试验进展及计划中的监管讨论更新","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","BK4139"],"gpt_icon":0},{"id":"2578238486","title":"Solid Biosciences Inc.盘中异动 早盘股价大涨5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578238486","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578238486?lang=zh_cn&edition=full","pubTime":"2025-10-27 21:34","pubTimestamp":1761572055,"startTime":"0","endTime":"0","summary":"北京时间2025年10月27日21时34分，Solid Biosciences Inc.股票出现异动，股价快速拉升5.34%。截至发稿，该股报5.92美元/股，成交量3.8172万股，换手率0.05%，振幅3.56%。Solid Biosciences Inc.股票所在的生物技术行业中，整体涨幅为0.89%。其相关个股中，Avidity Biosciences, Inc.、戴纳基、Ethzilla Corporation C/Wts 06/11/2025涨幅较大，Nls Pharmaceutics Ltd.、Cellectar Biosciences, Inc.、Aditxt, Inc.较为活跃，换手率分别为138.64%、111.87%、85.93%，振幅较大的相关个股有冠科美博、Zenas Biopharma, Inc.、Fate Therapeutics, Inc.，振幅分别为19.22%、15.78%、10.90%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251027213415a6d0e725&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251027213415a6d0e725&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLDB","BK4139"],"gpt_icon":0},{"id":"1168836764","title":"Solid Biosciences宣布与Kinea Bio达成许可协议，授权使用专有下一代衣壳AAV-SLB101","url":"https://stock-news.laohu8.com/highlight/detail?id=1168836764","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168836764?lang=zh_cn&edition=full","pubTime":"2025-09-23 20:02","pubTimestamp":1758628923,"startTime":"0","endTime":"0","summary":"Solid Biosciences宣布与Kinea Bio达成许可协议，授权使用专有下一代衣壳AAV-SLB101","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLDB"],"gpt_icon":0},{"id":"2568260031","title":"Solid Biosciences Inc.盘中异动 大幅下挫5.15%报5.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568260031","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568260031?lang=zh_cn&edition=full","pubTime":"2025-09-20 00:05","pubTimestamp":1758297953,"startTime":"0","endTime":"0","summary":"北京时间2025年09月20日00时05分，Solid Biosciences Inc.股票出现波动，股价快速下跌5.15%。Solid Biosciences Inc.股票所在的生物技术行业中，整体跌幅为0.15%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。消息层面，截至00时05分，《H.C. Wainwright维持Solid Biosciences买入评级，维持目标价20美元》资讯为影响Solid Biosciences Inc.的重要信息。根据TipRanks数据显示，该分析师近一年总胜率为52.5%，总平均回报率为28.1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250920000554979d7f17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250920000554979d7f17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SLDB"],"gpt_icon":0},{"id":"2561402526","title":"Solid Biosciences Inc.盘中异动 大幅拉升5.48%报5.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2561402526","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561402526?lang=zh_cn&edition=full","pubTime":"2025-08-22 22:06","pubTimestamp":1755871597,"startTime":"0","endTime":"0","summary":"北京时间2025年08月22日22时06分，Solid Biosciences Inc.股票出现异动，股价大幅拉升5.48%。截至发稿，该股报5.97美元/股，成交量7.9083万股，换手率0.10%，振幅4.43%。Solid Biosciences Inc.股票所在的生物技术行业中，整体涨幅为0.28%。其相关个股中，Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Pmgc Holdings Inc.、Abpro Holdings Inc C/Wts 12/11/2029 涨幅较大，Pmgc Holdings Inc.、Azitra Inc、Genprex, Inc.较为活跃，换手率分别为5570.19%、485.90%、228.09%，振幅较大的相关个股有Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Pmgc Holdings Inc.、Moolec Science Sa C/Wts ，振幅分别为236.62%、69.84%、63.57%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822220638a6f5b3ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250822220638a6f5b3ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLDB","BK4139"],"gpt_icon":0},{"id":"2558141666","title":"Solid Biosciences Inc.盘中异动 股价大跌5.20%报5.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558141666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558141666?lang=zh_cn&edition=full","pubTime":"2025-08-11 21:48","pubTimestamp":1754920106,"startTime":"0","endTime":"0","summary":"北京时间2025年08月11日21时48分，Solid Biosciences Inc.股票出现异动，股价急速跳水5.20%。截至发稿，该股报5.96美元/股，成交量6.2685万股，换手率0.08%，振幅3.97%。Solid Biosciences Inc.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Entero Therapeutics Inc.、Equillium, Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大，Entero Therapeutics Inc.、Equillium, Inc.、Io Biotech, Inc.较为活跃，换手率分别为2940.05%、269.76%、83.34%，振幅较大的相关个股有Entero Therapeutics Inc.、Equillium, Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 ，振幅分别为74.27%、70.46%、30.00%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811214827a4821dcb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811214827a4821dcb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLDB","BK4139"],"gpt_icon":0},{"id":"2557562337","title":"Solid Biosciences Inc.盘中异动 股价大跌5.22%报6.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557562337","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557562337?lang=zh_cn&edition=full","pubTime":"2025-08-07 22:46","pubTimestamp":1754578001,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日22时46分，Solid Biosciences Inc.股票出现波动，股价急速下挫5.22%。截至发稿，该股报6.17美元/股，成交量17.1639万股，换手率0.22%，振幅4.76%。Solid Biosciences Inc.股票所在的生物技术行业中，整体跌幅为0.22%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Omniab Inc C/Wts 、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Palisade Bio, Inc.、Bioxcel Therapeutics, Inc.、Processa Pharmaceuticals, Inc.较为活跃，换手率分别为1668.69%、125.23%、82.02%，振幅较大的相关个股有Palisade Bio, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Briacell Therapeutics Corp C/Wts 26/02/2026，振幅分别为92.00%、64.39%、39.49%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807224641a6d916c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807224641a6d916c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SLDB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.solidbio.com","stockEarnings":[{"period":"1week","weight":-0.0031},{"period":"1month","weight":0.1798},{"period":"3month","weight":0.4597},{"period":"6month","weight":-0.0123},{"period":"1year","weight":1.022},{"period":"ytd","weight":0.1401}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.099},{"period":"1year","weight":0.1555},{"period":"ytd","weight":0.0198}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Solid Biosciences Inc.前称是“SOLID Ventures Management, LLC”，成立于2013年3月，最初是作为一家特拉华州有限责任公司成立的。该公司是一家生命科学公司，专注于推进当前和未来基因治疗候选药物组合，该公司将其统称为候选药物，包括用于治疗杜氏肌营养不良症的SGT-003，或Duchenne，用于治疗儿茶酚胺能多形性室性心动过速（CPVT）的SGT-501，以及用于治疗心脏和疾病的额外资产，处于不同的发展阶段，投资水平不同。该公司正在推进涉及罕见神经肌肉和心脏疾病的多样化管道，汇集科学、技术、疾病管理和护理方面的专家。以患者为中心，由直接受到Duchenne影响的人创立，该公司的使命是改善患有这些毁灭性疾病的患者的日常生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.034906},{"month":2,"riseRate":0.444444,"avgChangeRate":0.032145},{"month":3,"riseRate":0.25,"avgChangeRate":-0.133214},{"month":4,"riseRate":0.25,"avgChangeRate":-0.019482},{"month":5,"riseRate":0.5,"avgChangeRate":0.039925},{"month":6,"riseRate":0.5,"avgChangeRate":0.097337},{"month":7,"riseRate":0.5,"avgChangeRate":0.085176},{"month":8,"riseRate":0.375,"avgChangeRate":-0.007542},{"month":9,"riseRate":0.375,"avgChangeRate":-0.06872},{"month":10,"riseRate":0.25,"avgChangeRate":-0.04082},{"month":11,"riseRate":0.625,"avgChangeRate":-0.055728},{"month":12,"riseRate":0.5,"avgChangeRate":0.250324}],"exchange":"NASDAQ","name":"Solid Biosciences","nameEN":"Solid Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Solid Biosciences(SLDB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Solid Biosciences(SLDB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Solid Biosciences,SLDB,Solid Biosciences股票,Solid Biosciences股票老虎,Solid Biosciences股票老虎国际,Solid Biosciences行情,Solid Biosciences股票行情,Solid Biosciences股价,Solid Biosciences股市,Solid Biosciences股票价格,Solid Biosciences股票交易,Solid Biosciences股票购买,Solid Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Solid Biosciences(SLDB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Solid Biosciences(SLDB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况